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Abstract
Objective: Pericardial patches are commonly used in vascular surgery to close arteriotomies. The mechanism of early
healing after patch implantation is still not well defined. We used a rat aortic patch model to assess pericardial patch healing
and examined Ephrin-B2, a marker of arterial identity, expression within the post-implantation patch. We also determined
whether endothelial progenitor cells (EPC) are associated with early patch healing in the arterial environment.
Methods: Wistar rats (200–250 grams) underwent infrarenal aortic arteriotomy and then closure via bovine or porcine
pericardial patch angioplasty. Control groups included subcutaneously implanted patches. Patches were harvested at 0–
30 days and analyzed by histology, immunohistochemistry, immunofluorescence and Western blot as well as quantitative
PCR.
Results: Prior to implantation, pericardial patches are largely composed of collagen and are acellular. Following arterial
implantation, increasing numbers of CD68-positive cells as well as Ephrin-B2 and CD34 dual-positive cells are found within
both bovine and porcine pericardial patches, whereas the infiltrating cells are negative for vWF and a-actin. Porcine patches
have a luminal monolayer of cells at day 7, compared to bovine patches that have fewer luminal cells. Subcutaneously
implanted patches do not attract Ephrin-B2/CD34-positive cells. By day 30, both bovine and porcine pericardial patches
develop a neointima that contains Ephrin-B2, CD34, and VEGFR2-positive cells.
Conclusion: Both CD68-positive and Ephrin-B2 and CD34 dual-positive cells infiltrate the pericardial patch early after
implantation. Arteriotomy closure via pericardial patch angioplasty shows patch adaptation to the arterial environment that
may involve a foreign body response as well as localization of EPC. Arterial remodeling of pericardial patches support
endothelialization and may represent a paradigm of healing of scaffolds used for tissue engineering.
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Introduction
The use of patch angioplasty during carotid endarterectomy
and other arterial closure has become standard in vascular surgery
as patch use is associated with improved patient outcomes
including reduced risk of restenosis [1,2,3]. Debates regarding
the optimal patch material, however, continue, and have
prompted investigation into which material offers optimal
performance. The bovine pericardial patch was first introduced
in the 1990s and has become a commonly used material for
closure of the surgical angioplasty site [4,5]. Pericardium possesses
many merits including biocompatibility, easy handling, minimal
suture line bleeding, and ability to perform Doppler investigations
through the patch. Interestingly, despite use of bovine pericardial
patches in human patients for almost two decades, long-term
results for this biomaterial remain poorly documented, and the
mechanism of healing after patch implantation likewise remains
unknown. In particular, it is not even known whether cells
infiltrate the patch or whether these patches support endothelia-
lization when placed into the arterial circulation.
Historically, bioprosthetic heart valves were one of the first
successful applications of engineered tissue, and the introduction of
gluteraldehyde preservation in 1969 only served to further
enhance their clinical utility. Preliminary results using early
unfixed bioprosthetic tissues found them to be immunogenic and
susceptible to early degradation, weakening, and failure. The
application of gluteraldehyde cross-linking to these engineered
tissues decreased the observed immunogenicity and likewise
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quickly became evident in the increasingly common usage of
bioprosthetic cardiac valves. Similarly, the gluteraldehyde-fixed
umbilical cord was also an important successful arterial conduit for
human patients with peripheral vascular disease [6,7].
Along with increased clinical usage came the early observation
that high concentrations of gluteraldehyde used for preservation
allowed for less in vivo remodeling and had an increased tendency
to calcify [8]. Newer generation bioprosthetics were able to
successfully use lower concentrations of gluteraldehyde while
preserving reduced immunogenicity [9]. Modern bioprosthetics,
such as the latest generation of the bovine pericardial patch,
continue to use low concentrations of gluteraldehyde in combina-
tion with decellularization, the removal of cellular and nuclear
material; in addition the gluteraldehyde is removed prior to
surgical implantation into patients. These methods have led to the
most recent generation of bioprosthetic patches that may allow for
in vivo remodeling and adaptation. Studies using the rat
subcutaneous implantation model have found that these properties
allow for fibroblast ingrowth and cellular incorporation coupled
with preservation of durability [9]. However, it is not known to
what extent remodeling and arterial adaptation, such as
endothelialization, occur with patch closure, as well as any
differences that might occur in pericardial patches that are not
fixed with gluteraldehyde.
Prior work in vein grafts has shown the complexity of venous
adaptation to the arterial environment [10]. We have previously
shown that arterialized vein grafts show increased cellularity and
matrix in all layers of the vessel wall, as well as diminished
expression of the venous marker Eph-B4, yet they fail to express
Ephrin-B2, a marker of arterial identity [11]. Since pericardium is
not derived from a vessel, and therefore does not express either
Ephrin-B2 nor Eph-B4, it is not clear whether this biomaterial is
capable of adopting an arterial identity and expressing Ephrin-B2
[12].
Accordingly, we examined commercially-available pericardial
patches in an arterial patch closure model to determine the
mechanisms by which these patches support arterial healing. We
hypothesize that once placed into an arterial environment, the
pericardial patches will support cellular influx and these entering
cells express the arterial marker Ephrin-B2 in addition to CD34, a
marker of neovascularization; in addition, we hypothesize that
pericardial patches support endothelialization of the patch on its
luminal surface. We also tested the hypothesis that pericardial




All experiments were approved by the Institutional Animal Care
and Use Committee at the Yale University School of Medicine
(IACUC# 2010–10896). Young (6–8 week-old) male Wistar rats
(mean weight, 209634 g) were use for patch implantation (n=24).
Anesthesia was performed via isoflurane inhalation with surgery
performed using a dissecting microscope (Leica MZ 95, Germany).
An abdominal midline incision was made and the infrarenal
abdominal aorta was exposed and dissected free of surrounding
structures. Following subcutaneous heparin injection (100 U/
100 g) the infrarenal aorta was clamped. A longitudinal 3 mm
arteriotomy was then made on the anterior aortic wall and a
pericardial patch (3 mm61 mm) was sutured in place using
interrupted 10-0 nylon (Figure 1; bovine: Synovis Life Technol-
ogies, St. Paul, MN, USA; porcine: Tissue Regenix, York, United
Kingdom). After completion of the angioplasty, the micro-clamps
were removed and aortic flow was restored. The abdomen was
then closed using 5-0 Dacron sutures. Additional age-matched
Wistar rats were used for subcutaneous patch implantation
(n=12). Animals were sacrificed on postoperative days 1, 3, 7,
or 30. No immunosuppressive agents were given at any time.
Histology
Rats were anesthetized with isoflurane, and tissues were fixed by
transcardial perfusion of phosphate buffered saline (PBS) followed
by 10 percent formalin. Tissue was removed and fixed overnight in
10 percent formalin followed by a 24-hour immersion in 70
percent alcohol. Tissue was then embedded in paraffin and
sectioned. H&E stained sections were used for cell counts; 4
random representative high power fields were counted from each
patch and the mean number of cells in each high power field
recorded.
Immunohistochemistry
Tissue sections were de-paraffinized using xylene and a graded
series of alcohols. Sections were then incubated in peroxidase
blocking solution and stained using antibodies against von
Willebrand Factor (Dako, A0082), a-actin (Thermo Scientific,
MS-113), or CD68 (Thermo Scientific, MS-397) overnight at 4uC.
Immunohistochemical detection was performed using DAB as well
as NovaRED substrate (Vector). Sections were counterstained with
Mayer’s Hematoxylin.
Immunofluorescence
Tissue sections were de-paraffinized and stained using primary
antibodies against CD31 (BD Pharmingen, 550300), CD34 (R&D,
AF4117) Ephrin-B2 (Novus, NBP1-48610), or ED-1 (Abcam).
Appropriate fluorophore-conjugated secondary antibodies were
selected. An antifade reagent with DAPI nuclear stain (Invitrogen,
P-36931) was applied prior to cover slip placement.
PCR Analysis
Total RNA was isolated from tissue and patches using TRIzol
Reagent (Invitrogen) and RNA was cleaned using the RNeasy
Mini kit with digested DNase I (QIAGEN). For quantification of
total RNA, each sample was measured using the RiboGreen RNA
Assay kit (Invitrogen). RT was performed using the SuperScript III
First-Strand Synthesis Supermix (Invitrogen) according to the
manufacturer’s instructions. Real-time quantitative PCR was
performed using SYBR Green Supermix (Bio-Rad Laboratories)
and amplified for 40 cycles using the iQ5 Real-Time PCR
Detection system (Bio-Rad Laboratories). All samples were
normalized by GAPDH amplification. The sequences for the
primers to amplify Ephrin-B2 and GAPDH were synthesized
(Keck Oligonucleotide Synthesis Facility, Yale University, New
Haven, CT) and are shown in Table 1. Primers for CD34 were
purchased (SABiosciences, PPR55773A-200). Patches were ana-
lyzed individually, without combination of samples.
Western Blot Analysis
For protein extraction, the inferior vena cava, the pericardial
patch, and the thoracic aorta were carefully harvested separately
and snap-frozen in liquid nitrogen. Samples were crushed and
mixed with buffer including protease inhibitors (Roche, Complete
Mini 12108700) prior to sonication (5 sec) and centrifugation
(800 g, 20 min). Equal amounts of protein from each experimental
group were loaded for SDS-PAGE, followed by Western blot
analysis. The membranes were probed with antibodies against
Patches Heal via Ephrin-B2/CD34 Positive Cells
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GAPDH (Cell Signaling, 14C10). Membrane signals were
detected using the ECL detection reagent (Amersham, Buck-




To define the pattern of arterial healing with a common
clinically-used pericardial patch, bovine pericardial patches were
examined in a rat angioplasty model (Vascuguard; Synovis Life
Technologies, St. Paul, MN, USA). Prior to implantation bovine
pericardial patches are acellular (Figure 2). After implantation
into the rat aorta, cells increasingly infiltrated into the patch,
between the collagen fibers, with the number of infiltrating cells
directly correlating with length of time implanted (Figure 2). Cells
were present throughout the angioplasty patch; however, with
increasing time, cells migrated more centrally into the interior of
the patch compared to the fewer number of cells present on the
patch surface (Figure 2). Although subcutaneously implanted
patches also had an increasing cellular infiltrate, this infiltrate
remained predominantly on the periphery of the patch (Figure 2).
Arterial patches were also examined during the first week after
implantation for potential markers of cellular identity on the
infiltrating cells (Figure 3). At these early time points, an
endothelial cell layer was not readily apparent; infiltrating cells
were negative for vWF and a-actin, markers of vascular
endothelial cells and smooth muscle cells respectively, at all time
points (Figure 3). Immunofluorescence for CD31, an alternative
vascular endothelial cell marker, confirmed lack of endothelial
cells in arterial patches on days 1, 3, and 7 (data not shown). Some
of the infiltrating cells stained positively for CD68, consistent with
their being macrophages (Figure 3). In comparison, the cells
infiltrating into subcutaneously implanted patches developed
positive staining for vWF, a-actin and CD68 by postoperative
day 7 (Figure 3).
Since some of the cells infiltrating into arterial patches were not
positively stained with CD68, we examined these cells for markers
that would suggest endothelial or arterial progenitor cell identity.
Arterial patches (day 7) were examined using immunofluorescence
for both CD34 and Ephrin-B2 (Figure 3). Approximately half of the
infiltrating cells were positive for CD34 and the number of cells
appeared to increase, in a centrally concentrated position, over time;
similarly, Ephrin-B2 was detected on these cells in a mostly similar
pattern and that typically colocalized with CD34 (Figure 3).
However, cells infiltrating into the subcutaneously implanted patches
stained negative for both CD34 and Ephrin-B2 (Figure 3).Similarly,
some of the cells infiltrating into arterial patches were dually-positive
for CD34 and VEGFR2 by day 7, and none of these cells were
detected in subcutaneously implanted patches (Figure 3).
Figure 1. Photomicrographs of the implanted pericardial patch. A) The rat aorta after arteriotomy and prior to patch placement; the white
arrow shows the glistening intima on the posterior wall; ruler markings are 1mm. Scale bar, 1000 microns. B) Completed bovine patch closure. Scale
bar, 1000 microns. C) Completed porcine patch closure. Scale bar, 500 microns. D) Explanted aortic segment containing patch after harvesting and
flushing. Scale bar, 1000 microns. In each graph, A=aorta; P=pericardial patch.
doi:10.1371/journal.pone.0038844.g001
Table 1. Primer pairs used in the study.
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infiltrating into the arterial patches but not into the subcutaneously
placed patches, patches were explanted postoperatively and
mRNA extracted from them. qPCR analysis showed that arterial
patches had significant expression of both Ephrin-B2 (Figure 3A)
and CD34 (Figure 3B) postoperatively, whereas there was
minimal Ephrin-B2 (Figure 3D) and CD34 (Figure 3E)
expression present in subcutaneously placed patches,. The increase
in Ephrin-B2 expression in arterial patches also increased over
time when compared to the amount present in the inferior vena
cava, although it did not reach the amount present in aorta (data
not shown).
Patches were similarly examined for protein expression
(Figure 3). Western blot analysis confirmed the presence of
Ephrin-B2 and CD34 protein expression within the patches when
placed in the arterial (Figure 3C) but not the subcutaneous
position (Figure 3F). All levels of protein expression were lower in
the angioplasty patch groups when compared to native aorta; no
protein expression was found in the pre-implantation patch
(Figures 3C, 3F).
Porcine patches
To determine the effect of gluteraldehyde cross-linkage of the
patch, we examined porcine pericardial patches that are
decellularized by a different manufacturing process that does not
use gluteraldehyde (dCELL; Tissue Regenix, York, United
Kingdom). Examination of these porcine patches with immuno-
fluorescence shows that these patches are acellular prior to
implantation (Figure 4), similar to bovine patches (Figure 3).
Also similar to bovine patches, cells infiltrating into the porcine
patches stained positively for CD34, Ephrin-B2, VEGFR2, or
CD68 (Figure 4). However, unlike bovine patches that showed
predominantly cellular infiltration into the middle of the patch by
day 7 (Figures 2, 3), the luminal surface of the porcine patch is
covered by cells as early as day 7 after implantation; in addition,
these luminal cells are CD34 positive, with some of the cells also
being CD34 and Ephrin-B2 dual positive (Figure 4) as well as
CD34 and VEGFR2 dual positive (Figure 4). Western blot
confirmed that the patches contain Ephrin-B2 and CD34 protein
at day 7 (Figure 4B).
Patches were followed to 30 days; both bovine and porcine
patches demonstrated a thick layer of luminal neointima
(Figure 5A) that was of similar thickness between bovine and
porcine patches (Figure 5B). Examination of the explanted 30-
day patches with immunofluorescence showed that the neointima
of both patches was composed of cells that were positive for CD34,
Ephrin-B2, and VEGFR2, with minimal differences between
bovine and porcine neointima (Figure 5C). Western blot
confirmed the presence of Ephrin-B2 and CD34 protein in both
bovine and porcine pericardial patches (Figure 5D).
Figure 2. Increasing numbers of infiltrating cells into the arterial patch. A) Photomicrographs of bovine pericardial patches, implanted into
either an arterial or subcutaneous position, and shown at either high or low magnification. Scale bar, 40 microns. B) Graph of cell count in the patch
over time; mean of 4 high power fields per patch; n=2. *, p,0.0001.
doi:10.1371/journal.pone.0038844.g002
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We show that pericardial patches support cell infiltration after
implantation into the arterial circulation. Within the first week of
implantation of a bovine pericardial patch into an arterial position
but not in a subcutaneous position, infiltrating cells express CD68,
Ephrin-B2 as well as CD34, but not vWF or alpha-actin, in the
middle of the patch and with fewer cells on the luminal surface.
Porcine pericardial patches show a similar pattern of cells
infiltrating into the middle of the patch, with additional detection
of luminal cells that are positive for CD34, Ephrin-B2, and
VEGFR2. These results suggest that surgical closure of an artery
with a pericardial patch supports arterial remodeling by
endothelialization of the luminal surface, at least in the short
term, not by ingrowth of endothelial cells or smooth muscle cells,
but rather by influx of arterial progenitor cells. However, by
30 days, both bovine and porcine patches develop similar amounts
of luminal neointima, suggesting that long term patency is
maintained by endothelialization, regardless of patch origin.
Acquisition of an arterial identity in the patch
A critical finding of this study is the detection of infiltrating cells
that express the arterial identity molecule, Ephrin-B2, as well as a
time-dependent increase in Ephrin-B2 mRNA expression in the
patches. This finding suggests that the mean number of Ephrin-B2
positive cells increases within the patch in time-dependent
manner. Ephrin-B2 and its receptor Eph-B4 are differentially
expressed in arteries and veins, with Ephrin-B2 an arterial marker
and Eph-B4 a venous marker [13,14]. The Ephrins and the Ephs
are the ligands and receptors, respectively, of the largest of the 14
subfamilies of the receptor tyrosine kinase families [15]. In the
developing cardiovascular system, ephrin and Eph molecules
control the angiogenic remodeling of blood vessels and lymphatic
vessels and play essential roles in endothelial cells as well as in
supporting pericytes and vascular smooth muscle cells [16].
However, not only are Ephrin-B2 and Eph-B4 expressed during
embryonic development and determination of the vasculature, but
Ephrin-B2 and Eph-B4 remain persistently expressed in adult
vessels. We have previously shown that Eph-B4 is active in adult
veins and regulates venous remodeling [17].
During vein graft adaptation to the arterial circulation, veins
lose their expression of Eph-B4, but they also fail to express an
arterial identity and do not increase expression of Ephrin-B2 or
members of the delta-notch pathway [11,18]. However, we show
that pericardial patches, unlike vein grafts, are capable of gaining
arterial identity, suggesting that pericardial patches can adapt to
the arterial circulation. Interestingly, arterial identity appears to be
expressed by cells infiltrating into the patch, whereas vein graft
Figure 3. Cells infiltrating into arterial, but not subcutaneous, patches have markers for either macrophages or arterial progenitor
cells. Scale bar, 10 microns, except 40 microns for subcutaneous histology. n=3; representative pictures are shown. Immunofluorescence shows
CD34 and Ephrin-B2-positive cells colocalize in the middle of the bovine arterial patch, day 7. Photomicrographs of immunofluorescence: blue color,
DAPI; green color, CD34; red color, Ephrin-B2; merge, green + red. n=3; representative pictures are shown. Scale bar, 10 microns. Similarly, merge of
CD34 and VEGFR2 is shown. Bar graphs show increased expression of Ephrin-B2 and CD34 mRNA and protein in arterial, but not subcutaneous,
patches. n=425. Panels A, B, D, and E, mRNA; Panels C and F, protein.
doi:10.1371/journal.pone.0038844.g003
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vein graft, with smooth muscle cell proliferation [11].
EPC play a role in patch remodeling
EPC play a critical role in vascular remodeling and adaptation.
EPC elicit neovascularization in response to ischemia, and repair
injured endothelium [19]._ENREF_15 Accordingly, autologous
EPC therapy has emerged as a promising treatment option for
critical limb ischemia secondary to its ability to promote
neovascularization and remodeling of pre-existent vessels
[20,21,22]. EPC are characterized by their unique surface marker
expression, and although many markers have been studied and
described, CD34 and VEGFR2 expression continue to be a
recognized identification method [19,23]. We used the marker
CD34 to identify progenitor cells within the implanted patch, and
expression of CD34 increased in a time-dependent manner from
day-1 through day-7, and continued to be present in the neointima
at day 30. Since the definition of EPC is not completely agreed
upon, with lack of consensus as to the definitive definition and
markers [24,25], it is clear that our identification of CD34-positive
cells may not definitively identify them as classic EPC. However,
colocalization of CD34-positive cells with Ephrin-B2 as well as
VEGFR2 (Figure 3) suggests that these cells infiltrating the patch
are arterial progenitor cells, although CD34 is present on surface
endothelial cells, preventing our ability to distinguish EPC from
endothelial cells (Figures 4, 5). Nevertheless, finding arterial
progenitor cells infiltrating into the patch is consistent with the
data that have found that coronary stent implantation may induce
mobilization and differentiation of bone marrow cells into
endothelial or smooth muscle cells [26]. EPC promote vascular
graft patency, and circulating EPC play an important role in
endothelial protection and integrity [27,28]. Current clinical trials
are attempting to exploit these characteristics by designing coated
stents that attract EPC in situ, with the belief that stents that are
capable of achieving this will have improved adaptation and be
better equipped to heal endothelium [29,30]. Application of these
findings to the pericardial patch may help direct more EPC to the
patch and aid in transfer of endothelial cells.
Subcutaneous patches fail to attract EPC
Examination of the subcutaneously implanted patches did not
reveal the presence of either CD34-positive or Ephrin-B2-positive
cells, thus failing to show arterial adaptation. As compared to the
arteriotomy patches, subcutaneously patches lacked exposure to
arterial shear flow as well as EPC exposure from within the
circulating blood pool. A confounding factor is the reduced
surgical trauma and associated lesser inflammatory response of a
subcutaneous implantation compared to an abdominal laparoto-
my, since EPC are mobilized from the bone marrow into the
peripheral circulation in response to surgical trauma [26,31].
Macrophages are known mediators of inflammation and their
presence within surgical sites is well established. As expected, a
large number of inflammatory cells were identified in the
neighboring tissues surrounding the patch, with many cells
infiltrating into the subcutaneously placed patch. We observed
some macrophages infiltrating into the arterial patches, although it
appeared that fewer macrophages infiltrated into the arterial
patches compared to the large numbers that infiltrated into the
subcutaneously placed patches.
One difference that might account for these results is the effect
of the patch environment on macrophage recruitment. The
extracellular matrix adjacent to the subcutaneous patch may
Figure 4. Porcine pericardial patches, day 7. A) Porcine pericardial patches show infiltrating cells positive for CD34, Ephrin-B2, VEGFR2, or CD68;
CD34-positive cells are present as a surface monolayer, with some cells dually positive for CD34 and Ephrin-B2 or CD34 and VEGFR2; first panel is the
day 0 (preimplantation) control. Photomicrographs of immunofluorescence: blue color, DAPI; green color, CD34; red color, Ephrin-B2 or VEGFR2;
merge, green + red. n=3; representative pictures are shown. Scale bar, 10 microns. B) Western blot of Ephrin-B2 and CD34, in porcine pericardial
patch, day 0 (preimplantation) or day 7.
doi:10.1371/journal.pone.0038844.g004
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of the arterial patches. Arterial flow and/or pressure may exert a
protective effect on the angioplasty patches that alters the
inflammatory response, although the outside surface of the arterial
patch is still exposed to the retroperitoneal tissues. This suggests
that macrophages may need a specific signal to infiltrate the patch,
or that the blood flow and/or pressure inside the vessel prevents a
chemoattractive signal gradient from being established. An
alternative consideration is that the early time course in this study
may prevent observation of a later macrophage influx. Since our
model only describes the course of healing until 30 days after
implantation, longer time data points are needed for a full
description of patch healing.
Bovine and porcine patches develop neointima
Although porcine patches show earlier luminal cells compared
to bovine patches (Figure 4), both patches develop a similar
amount of neointima on their luminal surface by 30 days
(Figure 5). As such, the significance of the earlier endothelializa-
tion of the porcine patches is not clear, as it may simply reflect
differences in timing between bovine and porcine patch healing.
Examination of bovine patches processed without gluteraldehyde
could potentially examine this issue, but these patches are not
currently available for surgical implantation in the vascular system.
However, since both patches develop luminal neointima by
30 days, we believe that the similarities between the bovine and
porcine pericardial patches, despite potential differences in their
manufacturing processes, will lead to similar clinical outcomes
when used in human patients. Since both patches support
endothelialization and development of luminal neointima, this
mode of healing predicts favorable long-term outcome, with good
patency rates and minimal rates of thrombosis, infection, or
pseudoaneurysm formation [3,32].
In summary, the results from our surgical angioplasty model
show that the pericardial patch is capable of supporting luminal
endothelialization, promoting vessel remodeling and arterial
adaptation. Ephrin-B2, CD34 and VEGFR2 positive cells were
successfully identified within the implanted patch and may
represent arterial or EPC. Increased Ephrin-B2 expression in the
healing artery is distinctly different that the loss of Ephrin-B2/
Figure 5. Bovine and porcine pericardial patches, day 30. A) Representative photomicrographs of bovine and porcine patches, low (10x) and
high (40x) magnification, scale bar 80 and 30 (porcine, 40) microns. Arrow shows the neointima; arrowhead shows the patch; L, lumen. B) Bar graph of
mean neointimal thickness, bovine and porcine patches, day 30. C) Photomicrographs of immunofluorescence: blue color, DAPI; green color, CD34;
red color, Ephrin-B2 or VEGFR2; merge, green + red. n=2; representative pictures are shown. Scale bar, 10 microns. D) Western blot of Ephrin-B2 or
CD34, in bovine or porcine pericardial patch, day 0 (preimplantation) or day 30; n=2.
doi:10.1371/journal.pone.0038844.g005
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suggesting that arterial and venous remodeling are fundamentally
different. Arterial remodeling of pericardial patches may represent
a paradigm of healing of scaffolds used for tissue engineering.
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